Journal article icon

Journal article

Using viral load and epidemic dynamics to optimize pooled testing in resource-constrained settings

Abstract:
SARS-CoV-2 infections are characterized by viral proliferation and clearance phases and can be followed by low-level persistent viral RNA shedding. The dynamics of viral RNA concentration, particularly in the early stages of infection, can inform clinical measures and interventions such as test-based screening. We used prospective longitudinal quantitative reverse transcription PCR testing to measure the viral RNA trajectories for 68 individuals during the resumption of the 2019-2020 National Basketball Association season. For 46 individuals with acute infections, we inferred the peak viral concentration and the duration of the viral proliferation and clearance phases. According to our mathematical model, we found that viral RNA concentrations peaked an average of 3.3 days (95% credible interval [CI] 2.5, 4.2) after first possible detectability at a cycle threshold value of 22.3 (95% CI 20.5, 23.9). The viral clearance phase lasted longer for symptomatic individuals (10.9 days [95% CI 7.9, 14.4]) than for asymptomatic individuals (7.8 days [95% CI 6.1, 9.7]). A second test within 2 days after an initial positive PCR test substantially improves certainty about a patient's infection stage. The effective sensitivity of a test intended to identify infectious individuals declines substantially with test turnaround time. These findings indicate that SARS-CoV-2 viral concentrations peak rapidly regardless of symptoms. Sequential tests can help reveal a patient's progress through infection stages. Frequent, rapid-turnaround testing is needed to effectively screen individuals before they become infectious
Publication status:
Published
Peer review status:
Peer reviewed

Actions

Access Document

Files:
Publisher copy:
10.1126/scitranslmed.abf1568

Authors

More by this author
Role:
Author
ORCID:
0000-0003-0825-7129
More by this author
Institution:
University of Oxford
Role:
Author
ORCID:
0000-0002-1998-1844
More by this author
Role:
Author
ORCID:
0000-0002-3607-6416
More by this author
Role:
Author
ORCID:
0000-0003-3035-5630


Publisher:
American Association for the Advancement of Science
Journal:
Science Translational Medicine More from this journal
Volume:
13
Issue:
589
Pages:
eabf1568
Publication date:
2021-02-22
DOI:
EISSN:
1946-6242
ISSN:
1946-6234


Language:
English
Keywords:
Pubs id:
2370955
Local pid:
pubs:2370955
Source identifiers:
W3130371474
Deposit date:
2026-02-13
ARK identifier:
This ORA record was generated from metadata provided by an external service. It has not been edited by the ORA Team.

Terms of use


Views and Downloads






If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP